Duration variability is a mechanistic pharmacokinetic construct describing how differences in the shape and timing of sildenafil exposure can produce different modeled duration geometries. The relevant sequence begins with drug input and absorption, continues through systemic exposure and distribution, and then progresses through metabolism, clearance, and elimination. Variability at any of these stages can alter the concentration–time trajectory, including the timing of the rising phase, the magnitude and location of the peak, the persistence of concentrations, and the slope of the declining phase. Duration geometry therefore represents a derived property of the complete exposure trajectory rather than a single fixed parameter. A trajectory with slower decline can display a wider modeled exposure interval, whereas a trajectory with faster decline can display a narrower interval under the same modeling definition. Absorption can also influence duration geometry indirectly because differences in input timing change the initial conditions from which disposition begins. Distribution can introduce additional persistence or redistribution phases, while metabolic and clearance variability directly alter the rate of concentration decline. This framework is distinct from clinical duration or effectiveness. It describes only how pharmacokinetic processes generate variable temporal exposure patterns. For comparison of temporal PK constructs, see duration comparison.
Absorption variability changes the temporal pattern by which sildenafil enters systemic circulation. Dissolution determines how quickly drug becomes available for absorption, while gastric emptying controls the timing of delivery from the stomach into the intestine. Differences in intestinal delivery can therefore shift both the beginning and slope of systemic input. A relatively concentrated input profile can produce a steeper early exposure rise, whereas a more dispersed input profile can spread systemic entry over a longer interval. These changes affect the concentration–time trajectory before disposition is considered independently. Importantly, absorption rate and absorption extent are distinct dimensions. A change in rate primarily modifies the timing and geometry of the ascending portion of the curve, while a change in extent alters the overall amount entering systemic circulation. When the absorption phase overlaps substantially with distribution and elimination, changes in input timing can also modify the apparent shape of the later concentration decline. Consequently, variability originating before systemic exposure can propagate into the modeled duration region without requiring any change in the intrinsic elimination process. Duration variability can therefore reflect differences in input geometry as well as differences in disposition. The mechanistic foundation of this process is described in absorption.
Exposure variability describes differences in the concentration–time trajectory created by variation in the amount and timing of systemic drug input. Two exposure profiles can differ in both Tmax and Cmax while subsequently undergoing similar elimination processes. Tmax represents the temporal location of the observed concentration maximum, so variability in Tmax shifts the position of the peak relative to the beginning of the exposure trajectory. Cmax represents the magnitude of that maximum and therefore establishes a different concentration starting point for the subsequent decline. These parameters interact with, but do not independently define, modeled duration. A higher or lower initial concentration can intersect a defined concentration boundary at a different time even when the elimination-rate constant is unchanged. Likewise, a shifted Tmax changes when the declining phase begins relative to the overall timeline. Exposure variability can therefore broaden the range of modeled duration values through differences in initial conditions rather than through changes in clearance itself. The distinction between timing and magnitude is important because Tmax primarily describes temporal positioning, whereas Cmax describes peak magnitude. Their variability can arise from differences in absorption rate, absorption extent, distribution, and input–disposition balance. These relationships are detailed through tmax and cmax.
Distribution variability modifies the relationship between systemic concentration and the movement of sildenafil between pharmacokinetic compartments. After systemic entry, drug may distribute between a central compartment and peripheral spaces according to concentration gradients, tissue partitioning, distribution volume, and transfer rates. Differences in these parameters alter how rapidly the central concentration changes and how much drug resides outside the central compartment at a given time. A faster distribution process can produce a more pronounced early redistribution component, whereas slower intercompartmental transfer can preserve a different central concentration trajectory. When peripheral compartments subsequently return drug to the central compartment, redistribution can contribute to the shape of the later concentration decline. This means that duration geometry is not necessarily determined by a single elimination process acting on a single homogeneous compartment. Multicompartment behavior can generate an initial distribution phase followed by a slower terminal phase, with the relative contribution of each phase varying according to distribution characteristics. Variability in distribution volume or intercompartmental transfer can therefore change the width and curvature of the modeled concentration–time profile even when metabolic activity is held constant. Distribution variability is consequently a disposition-level source of duration variability, distinct from absorption variability and metabolic clearance variability. The underlying compartmental processes are described in distribution.
Metabolism variability alters duration geometry by changing the rate at which sildenafil is converted into metabolites and removed through metabolic pathways. CYP3A4 is a major metabolic determinant, so variability in CYP3A4 turnover, catalytic capacity, substrate handling, or effective extraction can modify the metabolic component of disposition. A greater effective metabolic turnover can increase the rate at which parent drug is transformed, while lower turnover can reduce that component of elimination. The resulting concentration–time curve can therefore display different declining slopes even when absorption and distribution are otherwise identical. Metabolic variability may also interact with systemic exposure because changes in first-pass and systemic metabolism can alter the amount of parent drug reaching and remaining within the circulation. The mechanistic consequence is a change in the balance between drug input and drug removal. During the post-absorption phase, the removal component increasingly determines the direction and slope of the concentration trajectory. Variability in metabolic extraction can consequently propagate into different modeled persistence intervals. CYP3A4 turnover should be understood as one contributor within the broader hepatic metabolic system rather than as an isolated duration parameter. The general metabolic framework is described in metabolism, while enzyme-specific mechanisms are covered in cyp3a4.
Half-life variability represents variability in the rate at which drug concentration declines under a defined pharmacokinetic model. The half-life is mathematically related to the elimination-rate constant, with clearance and apparent distribution volume jointly influencing the observed rate of decline. Consequently, two trajectories can have different half-lives because their clearance differs, their effective distribution volume differs, or both components differ. When clearance is higher relative to the relevant distribution volume, concentration declines more rapidly; when clearance is lower, the decline can be slower. This changes the temporal distance between a given concentration and subsequent lower concentrations, producing different modeled duration persistence. Half-life therefore describes decline geometry rather than a therapeutic endpoint. In multicompartment systems, the observed concentration profile can contain several phases, meaning that a single reported half-life may summarize one particular phase or model-dependent component rather than the entire concentration–time trajectory. Variability in clearance can also interact with distribution because the same clearance value can produce different concentration-time behavior when the apparent distribution volume changes. Duration variability therefore cannot be reduced to half-life alone, although half-life provides an important mathematical descriptor of elimination-rate geometry. The relationship between half-life, clearance, and concentration decline is examined in half-life.
PK variability propagates into modeled PD variability because pharmacodynamic behavior is driven by the time-varying exposure generated by pharmacokinetic processes. Differences in absorption can shift the timing and slope of the concentration rise, while differences in exposure formation can alter Cmax, Tmax, and the amount of drug available to interact with the target system. Distribution variability can modify the relationship between plasma concentration and the concentration relevant to the effect compartment, creating temporal offsets or altered persistence in a modeled concentration–effect relationship. Metabolism and clearance variability then alter how rapidly systemic exposure falls. The combined result is a family of concentration–time trajectories rather than one invariant curve. When those trajectories are coupled to a pharmacodynamic model, differences in concentration magnitude and timing can propagate into differences in the modeled duration of the PD signal. This propagation does not imply a clinical outcome; it represents mathematical coupling between PK exposure and PD response. The resulting duration geometry depends on the chosen PK model, PD relationship, concentration threshold or effect function, and definition of the modeled duration interval. PK variability can therefore produce PD variability even when the pharmacodynamic mechanism itself is unchanged. Conversely, different PD sensitivities can alter how the same PK trajectory is mapped into a modeled PD interval. This distinction is central to pd variability.
Overall PK variability emerges from the combined variation of drug input, systemic exposure, distribution, metabolism, clearance, and elimination. At the input stage, dissolution and gastric emptying can alter when sildenafil becomes available for intestinal absorption. Absorption variability then changes the rate and extent of systemic entry, influencing the ascending concentration–time geometry. Exposure variability subsequently appears through differences in Tmax, Cmax, and overall concentration magnitude. Distribution variability changes the movement between central and peripheral compartments, which can alter both early concentration behavior and later redistribution. Metabolism variability, including differences in CYP3A4 turnover and extraction, changes the conversion and removal of parent drug. Clearance variability changes the rate at which systemic exposure is removed, while half-life variability summarizes corresponding differences in elimination-rate geometry under a defined model. These determinants can operate independently or interact, so the final duration profile is the integrated result of multiple PK processes. A change in one parameter can partially offset or amplify a change in another. For example, altered input timing can modify the apparent temporal placement of a decline even when intrinsic clearance is unchanged, while altered clearance can change persistence without changing the initial absorption pattern. Duration variability is therefore best represented as variability across complete exposure trajectories rather than as variability in one isolated parameter. This integrated framework is summarized in pk variability.
Absorption variability begins with differences in the rate and timing of drug availability for systemic entry. Dissolution controls the transition from the dosage form into a form available for absorption, while gastric emptying determines when dissolved material reaches the intestinal environment. Variability in these processes can distribute systemic input over different time intervals. A relatively rapid input produces a steeper ascending concentration–time phase, whereas delayed or dispersed input can flatten or extend that phase. Intestinal delivery therefore becomes an important temporal determinant of exposure formation even before systemic distribution or elimination is considered. Absorption rate should also be distinguished from absorption extent. Rate changes primarily modify the timing of exposure formation, while extent changes alter the total amount entering systemic circulation. When these properties vary together, both the magnitude and temporal position of the concentration profile can change. The resulting variability can propagate into the later duration region because the concentration trajectory enters the elimination phase from different initial conditions. The underlying input processes are described in absorption.
Absorption variability can produce duration spread because duration geometry is measured from a concentration–time trajectory whose initial conditions depend on systemic input. If drug enters the circulation over a shorter interval, the rising phase can become more concentrated in time. If entry is distributed over a longer interval, the ascending phase can become broader and overlap more extensively with the declining phase. This overlap changes the composite shape of the concentration curve even when clearance is unchanged. Differences in absorption extent can additionally shift the overall concentration magnitude, changing when a modeled concentration boundary is crossed during the decline. Thus, duration spread can arise from input geometry without requiring corresponding variability in elimination. Conversely, similar systemic exposure amounts can still produce different temporal profiles when the rate of absorption differs. The interaction between absorption and disposition means that duration geometry reflects the entire input–disposition system rather than an isolated absorption parameter. This relationship provides a mechanistic bridge between absorption variability and duration comparison.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Variability | Input differences. | absorption |
| Exposure Formation | Duration spread. | duration comparison |
Tmax variability represents variability in the time at which the concentration–time trajectory reaches its maximum. Because Tmax is determined by the balance between drug input and drug disposition, shifts in absorption rate or extent can move the peak earlier or later within the modeled trajectory. A delayed Tmax shifts the temporal location of the peak and therefore changes the point from which the principal declining phase is interpreted. A faster input profile can move the peak toward an earlier time, while a more dispersed input profile can extend the rising phase. Tmax does not independently determine the magnitude of exposure or the elimination rate; it is a temporal descriptor emerging from the interaction of absorption and disposition. Variability in Tmax can nevertheless influence duration geometry because duration is measured along the same concentration–time axis. When the peak is temporally displaced, subsequent concentration crossings occur at different positions relative to the original dosing or input time. Tmax variability therefore represents one pathway through which input differences propagate into duration variability. The temporal meaning of this parameter is described in tmax.
Cmax variability represents differences in peak concentration magnitude and therefore changes the concentration level from which the subsequent decline begins. Under a defined elimination process, a higher starting concentration requires a longer time to reach any fixed lower concentration than a lower starting concentration, assuming the same elimination geometry. Conversely, a lower initial concentration can intersect the same modeled boundary earlier. This mathematical relationship means that Cmax variability can broaden modeled duration values even when clearance and half-life remain unchanged. Cmax itself is influenced by absorption rate, absorption extent, bioavailability, distribution, and the overlap between input and elimination. It should therefore be treated as an emergent exposure parameter rather than an independent cause of variability. A change in Cmax can alter the vertical scale of the concentration–time trajectory, while a change in Tmax alters its horizontal positioning. Their combined variability changes the geometry of the peak and subsequent decline. The mechanistic role of peak magnitude is detailed in cmax.
Distribution variability reflects differences in how sildenafil moves between the central circulation and peripheral compartments. The relevant determinants include apparent distribution volume, tissue partitioning, concentration gradients, and intercompartmental transfer rates. A change in transfer rate can modify the speed at which central concentration falls during the distribution phase, while a change in distribution volume can alter the concentration produced by a given amount of drug within the modeled compartment. These processes can create a concentration profile with more than one temporal phase. An early distribution component may be followed by a slower terminal decline, and the relative contribution of those phases can vary across parameter sets. Distribution therefore affects duration geometry not simply by increasing or decreasing concentration, but by changing how drug mass is partitioned over time. If peripheral compartments retain drug and later return part of that drug to the central compartment, redistribution can alter the curvature and persistence of the terminal profile. This produces duration variability even when the metabolic elimination process is unchanged. The general compartmental framework is described in distribution.
Distribution variability can translate into differences in duration width because modeled persistence depends on the complete concentration trajectory, including distribution and redistribution phases. A profile dominated by rapid central-to-peripheral transfer may display a pronounced early decline followed by a slower phase, whereas altered transfer rates can redistribute that curvature across time. Peripheral retention can also create a reservoir-like compartment from which drug returns to the central compartment as concentrations fall. This return can flatten a later portion of the concentration–time curve without requiring a change in metabolic clearance. Consequently, two profiles with comparable initial exposure can display different terminal shapes because their compartmental exchange differs. The magnitude of distribution volume also affects the concentration associated with a given amount of drug, which can modify the apparent elimination slope when clearance is expressed relative to volume. Duration variability arising from distribution is therefore a disposition phenomenon involving compartmental geometry, transfer rates, and redistribution rather than a direct measure of therapeutic persistence. A deeper mechanistic treatment appears in distribution deep dive.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Distribution Variability | Persistence variability. | distribution |
| Redistribution | Duration variability. | distribution deep dive |
CYP3A4 turnover variability changes the metabolic component of sildenafil disposition by altering the effective capacity for enzymatic conversion. In a mechanistic model, differences in enzyme abundance, catalytic activity, or turnover can change the relationship between parent-drug concentration and metabolic removal. The resulting effect is expressed through the rate at which parent sildenafil is converted into metabolites and consequently disappears from the relevant parent-drug compartment. When metabolic capacity is higher, the metabolic component of the concentration decline can become steeper; when capacity is lower, that component can become less steep. The precise relationship depends on the kinetic regime and on how metabolism interacts with other elimination pathways. CYP3A4 activity can also influence systemic exposure through first-pass processes, thereby changing the amount of parent drug entering the circulation in addition to changing post-absorption removal. This creates a mechanistic connection between exposure formation and elimination geometry. CYP3A4 variability should therefore be considered one component of the broader metabolic system rather than a standalone duration parameter. The enzyme-specific mechanism is described in cyp3a4.
Extraction variability describes differences in the fraction and rate of sildenafil removed through metabolic processing and related hepatic disposition processes. Changes in effective extraction can alter systemic clearance, which in turn changes the slope of the post-absorption concentration–time trajectory. When extraction contributes substantially to total clearance, variability in extraction can become visible as variability in the elimination phase. However, the resulting duration geometry also depends on distribution volume and any remaining input from absorption. The same metabolic clearance can therefore generate different concentration trajectories if the distribution characteristics differ, just as the same distribution geometry can generate different declines when clearance changes. Metabolism and clearance are consequently coupled elements of the input–disposition system. A faster metabolic removal process reduces parent-drug persistence in the modeled system, whereas slower removal extends the concentration decline. These statements describe only concentration kinetics and do not imply a clinical outcome or effectiveness difference. The broader relationship between metabolic transformation and drug removal is covered in metabolism.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| CYP3A4 Variability | Turnover differences. | cyp3a4 |
| Extraction Variability | Elimination geometry. | metabolism |
Half-life variability represents variability in the characteristic time associated with concentration decline under a defined pharmacokinetic model. For a simple first-order elimination process, half-life is related to the elimination-rate constant through the logarithmic relationship between concentration and time. Clearance and apparent distribution volume determine that rate constant, so changes in either parameter can modify half-life. Higher clearance relative to the relevant distribution volume produces a faster decline, whereas lower clearance produces a slower decline. The resulting concentration–time curves therefore have different slopes and different temporal spacing between equivalent concentration levels. Half-life is consequently a descriptor of elimination-rate geometry rather than a measure of clinical duration. In more complex models, multiple disposition phases may exist, and the reported half-life may describe a terminal component rather than the entire trajectory. Distribution and redistribution can therefore influence the apparent half-life even when metabolic conversion itself is unchanged. Likewise, metabolic variability can alter clearance and thereby shift the half-life. This makes half-life a useful summary of decline behavior while still requiring interpretation within the underlying PK model. The mathematical relationship is described in half-life.
Half-life variability can modify duration persistence because a slower modeled decline requires more time for concentration to traverse the same range of values, while a faster decline traverses that range more rapidly. If duration is defined by the time during which concentration remains above a specified model threshold, half-life variability changes the threshold-crossing time even when the threshold itself is fixed. However, half-life does not uniquely determine duration because the starting concentration, absorption profile, distribution behavior, and threshold definition also influence the interval. A higher Cmax combined with the same half-life can produce a different duration geometry from a lower Cmax, while a different distribution volume can alter the observed decline despite similar clearance. In multicompartment models, terminal half-life may also reflect redistribution rather than a single metabolic process. Thus, half-life variability should be interpreted as one component of a larger disposition geometry. It describes the rate of concentration decay and provides a mathematical bridge between clearance and persistence, but it does not itself represent a therapeutic endpoint. The relationship between elimination kinetics and half-life is explored further in half-life deep dive.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Half-Life Variability | Decline variability. | half-life |
| Clearance Variability | Duration persistence. | half-life deep dive |
Absorption variability is one component of overall PK variability because the systemic concentration trajectory begins with the rate and extent of drug input. Dissolution, gastric emptying, intestinal delivery, and absorption processes can vary independently or in combination, producing different input functions. A faster input function concentrates systemic entry into a narrower time interval, while a slower input function spreads entry across a broader interval. These differences modify the rising phase and can alter the timing and magnitude of the peak. When the absorption phase overlaps with elimination, the observed concentration curve becomes the composite result of continuing input and simultaneous removal. Consequently, duration geometry can differ even when downstream metabolic clearance is held constant. Absorption extent also changes the total amount entering systemic circulation, which can alter the concentration level reached during the peak and the subsequent time required to cross a modeled concentration boundary. Overall PK variability therefore begins before the disposition phase and can propagate through every later part of the concentration–time profile. The integrated treatment of these processes is described in pk variability.
Metabolism and clearance variability alter the declining portion of the concentration–time curve by changing the rate at which sildenafil is removed from the systemic system. Differences in CYP3A4-mediated turnover can change metabolic extraction, while differences in total clearance modify the effective elimination rate. The magnitude of these effects depends on the distribution volume and on the compartmental model used to represent disposition. A higher clearance-to-volume relationship produces a steeper decline, whereas a lower relationship produces a flatter decline and longer persistence within the modeled concentration range. Distribution can further modify the observed terminal profile by transferring drug between central and peripheral compartments. Consequently, clearance variability cannot be interpreted independently from distribution variability when the concentration–time curve is modeled using multiple compartments. Half-life provides a summary of the resulting elimination-rate geometry, but it does not replace the underlying clearance and distribution parameters. The combined result is variability in the slope, curvature, and temporal extent of the declining exposure profile. These mechanisms are part of the broader framework of pk variability.
PK → PD variability occurs when differences in the pharmacokinetic trajectory are propagated through a pharmacodynamic relationship. Variability in absorption changes when exposure begins and how rapidly concentration rises. Variability in Cmax changes the magnitude of the exposure peak, while Tmax variability shifts its temporal location. Distribution variability can create temporal differences between plasma concentration and the concentration represented by a modeled effect compartment. Metabolism and clearance variability then modify how quickly the exposure signal declines. When these changing concentration profiles are coupled to a PD model, the resulting modeled response trajectory can differ in timing, magnitude, or persistence. This is a mathematical consequence of coupling a variable PK input to a concentration–effect relationship rather than a statement about clinical outcomes. The exact propagation depends on the PD function, effect-compartment assumptions, concentration threshold, and definition used for the modeled duration interval. Therefore, PK duration variability can generate corresponding PD-duration variability without requiring any change in the underlying target mechanism. The distinction between pharmacokinetic and pharmacodynamic variability is examined in pd variability.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Variability | Input variability. | pk variability |
| Metabolism & Clearance Variability | Decline variability. | pk variability |
| PK → PD Variability | Propagation. | pd variability |
Duration variability means that the modeled time-course of sildenafil exposure can differ across pharmacokinetic parameter sets. The relevant geometry is generated by the interaction of absorption, systemic exposure, distribution, metabolism, clearance, and elimination. Differences in absorption can shift the timing and slope of the rising concentration phase. Differences in exposure formation can alter Cmax and Tmax, establishing different initial conditions for the later decline. Distribution variability can change central and peripheral compartment exchange, producing different curvature or persistence during later phases. Metabolic and clearance variability can change the elimination-rate constant and therefore the slope of concentration decline. Half-life variability summarizes corresponding differences in elimination-rate geometry under a specified model. Duration variability is therefore not a single biological property and does not represent clinical duration. It is a mathematical description of how different concentration–time trajectories occupy different temporal intervals under the same or different model definitions. The term specifically concerns PK duration geometry and the mechanisms that generate variation in that geometry.
Absorption variability influences duration geometry by changing the timing and extent of systemic drug input. Dissolution determines when drug becomes available for absorption, while gastric emptying influences when material reaches the intestinal site of absorption. Differences in intestinal delivery can therefore change the rate at which sildenafil enters systemic circulation. A rapid input profile can create a steeper ascending concentration phase, while a slower or more dispersed input profile can broaden that phase. Absorption extent also affects the total amount entering systemic circulation and can therefore alter the concentration level reached during the exposure peak. Because absorption and elimination may occur simultaneously, changes in input timing can alter the composite shape of the concentration–time curve even when clearance remains constant. The resulting duration geometry may therefore differ because the declining phase begins from different concentration levels or overlaps differently with continuing absorption. Absorption variability is consequently an upstream source of PK duration variability rather than a direct measure of clinical duration.
Half-life variability modifies duration persistence by changing the mathematical rate at which concentration declines under a defined pharmacokinetic model. In a simple first-order model, half-life is related to the elimination-rate constant, while the elimination-rate constant is influenced by clearance and the relevant distribution volume. A shorter half-life corresponds to a faster modeled decline, whereas a longer half-life corresponds to a slower decline. If duration is represented as the interval before concentration crosses a specified model threshold, different half-lives produce different threshold-crossing times. However, half-life does not determine that interval independently. The starting concentration, absorption profile, distribution behavior, and threshold definition also contribute to the resulting duration geometry. In multicompartment models, several decline phases may exist, so a reported half-life can represent a particular disposition phase rather than the entire exposure trajectory. Half-life variability therefore describes variability in elimination-rate geometry and concentration persistence, not a therapeutic difference or clinical duration.
Distribution variability shapes duration width by changing how sildenafil is partitioned between central and peripheral compartments over time. Differences in distribution volume, tissue partitioning, and intercompartmental transfer rates can alter the concentration observed in the central compartment after systemic entry. Rapid transfer into peripheral compartments may produce an early distribution decline, while slower transfer can produce a different central concentration trajectory. Peripheral compartments can also return drug to the central compartment as concentrations fall, creating redistribution that changes the curvature of the later concentration–time profile. These processes can generate multiple disposition phases, including an early distribution phase and a slower terminal phase. If duration is defined by the time spent above a model concentration boundary, changes in these phases can alter the width of the resulting interval. Distribution variability can therefore change modeled persistence without requiring a change in metabolic clearance. The effect depends on the compartmental structure and parameter values used in the PK model. Distribution width is consequently a property of the complete disposition trajectory rather than a direct clinical-duration measurement.
Overall PK duration variability results from variation across multiple linked stages of the pharmacokinetic trajectory. Absorption variability changes the timing and extent of systemic input through processes such as dissolution, gastric emptying, and intestinal delivery. Exposure variability changes parameters such as Cmax and Tmax, which establish the magnitude and temporal position of the concentration peak. Distribution variability modifies movement between central and peripheral compartments and can influence redistribution and terminal curvature. Metabolism variability, including differences in CYP3A4 turnover and extraction, changes the metabolic component of drug removal. Clearance variability alters the overall rate of systemic elimination, while half-life variability summarizes corresponding differences in decline geometry under a defined model. These determinants can interact rather than acting independently. A change in absorption can alter peak formation, while clearance determines how the resulting exposure declines. Distribution can modify the concentration associated with a given amount of drug, influencing the observed relationship between clearance and half-life. Overall duration variability is therefore the integrated result of input, exposure, distribution, metabolism, and elimination variability within the modeled PK system.